<?xml version="1.0" encoding="UTF-8"?>
<ref id="B98-marinedrugs-17-00374" class="ref">
 <label class="label">98.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Pierik</surname>
    <given-names class="given-names">M.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Joossens</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Van Steen</surname>
    <given-names class="given-names">K.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Van Schuerbeek</surname>
    <given-names class="given-names">N.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Vlietinck</surname>
    <given-names class="given-names">R.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Rutgeerts</surname>
    <given-names class="given-names">P.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Vermeire</surname>
    <given-names class="given-names">S.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases</article-title>
  <source class="source">Inflamm. Bowel. Dis.</source>
  <year class="year">2006</year>
  <volume class="volume">12</volume>
  <fpage class="fpage">1</fpage>
  <lpage class="lpage">8</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.1097/01.MIB.0000195389.11645.ab</pub-id>
  <?supplied-pmid 16374251?>
  <pub-id pub-id-type="pmid" class="pub-id">16374251</pub-id>
 </element-citation>
</ref>
